Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Grifols is most often covered alongside CSL Behring, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 6 for the same window.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Grifols is most often covered alongside CSL Behring, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 6 for the same window. Their average consequence score of 6 runs above the beat's 5.8 for that window. We currently track 1 Healthcare story that mention Grifols, all published on February 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grifols. Shared-story counts are live from our verified record — not editorial picks.
Market Peak
Projected valuation of $25.15 billion reached through global capacity expansion.
Current Milestone
Market valuation hits significant mid-term growth targets as supply meets latent demand.
Infrastructure Investment
Major fractionators announce multi-billion dollar investments in automated collection centers.
Supply Recovery
Plasma collection volumes begin to stabilize following pandemic-era disruptions.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by a significant expansion in plasma collection infrastructure. This growth reflects rising clinical demand for antibody therapies and improved supply chain efficiencies across major pharmaceutical hubs.
Source: portal.sina.com.hk · manilatimes.net
Grifols is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
